Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX)

Historical Holders from Q3 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
BCAX on Nasdaq
Shares outstanding
54,347,826
Price per share
$16.83
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
49,994,786
Total reported value
$789,088,187
% of total 13F portfolios
0%
Share change
-1,056,866
Value change
+$2,780,401
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
112
Price from insider filings
$4.44
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Invus Global Management, LLC 9.6% $68,029,276 5,216,969 Raymond Debbane 30 Jun 2025
Vestal Point Capital, LP 9.2% +82% $59,550,000 +$26,571,508 5,000,000 +81% Vestal Point Capital, LP 30 Jun 2025
FMR LLC 5.1% +8% $35,941,070 +$2,840,282 2,756,217 +8.6% FMR LLC 10 Jul 2025
As of 30 Sep 2025, Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX) has 112 institutional shareholders filing 13F forms. They hold 49,994,786 shares. of 54,347,826 outstanding shares (92%) .

Top 25 institutional shareholders own 84% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 13% 6,955,993 0% 1.4% $109,835,129
Siren, L.L.C. 9.6% 5,216,969 0% 3.2% $82,375,941
Vestal Point Capital, LP 9.4% 5,100,000 +2% 3.7% $80,529,000
RED TREE MANAGEMENT, LLC 5.8% 3,170,509 0% 60% $50,062,337
TPG GP A, LLC 5.5% 3,010,425 0% 2.6% $47,534,611
FMR LLC 5% 2,698,361 +6.3% 0% $42,607,120
Deep Track Capital, LP 4.5% 2,426,657 0% 1.1% $38,316,914
BlackRock, Inc. 4.3% 2,311,789 +9.5% 0% $36,503,145
Omega Fund Management, LLC 4.1% 2,204,650 0% 16% $34,811,424
VANGUARD GROUP INC 4% 2,200,925 +9.8% 0% $34,752,606
PRICE T ROWE ASSOCIATES INC /MD/ 3.2% 1,755,411 -18% 0% $27,719,000
Blackstone Inc. 2.3% 1,224,336 0% 0.08% $19,332,265
MILLENNIUM MANAGEMENT LLC 1.9% 1,014,892 +37% 0.01% $16,025,145
GEODE CAPITAL MANAGEMENT, LLC 1.5% 831,208 +24% 0% $13,127,637
FIL Ltd 1.5% 803,753 -21% 0.01% $12,691,260
ACORN CAPITAL ADVISORS, LLC 1.2% 643,382 0% 5.2% $10,158,996
STATE STREET CORP 1.1% 590,277 +9.1% 0% $9,320,474
Aisling Capital Management LP 1% 568,919 0% 2% $8,983,231
Schonfeld Strategic Advisors LLC 0.93% 504,085 +92% 0.06% $7,959,499
T. Rowe Price Investment Management, Inc. 0.86% 464,727 0% $7,339,000
BANK OF AMERICA CORP /DE/ 0.84% 456,621 +1.2% 0% $7,210,046
NAN FUNG TRINITY (HK) LTD 0.71% 384,885 +12% 0.61% $6,077,334
Rock Springs Capital Management LP 0.68% 370,666 +10% 0.34% $5,852,816
Woodline Partners LP 0.64% 348,690 0% 0.03% $5,505,815
Clearbridge Investments, LLC 0.6% 324,321 0% $5,121,029

Institutional Holders of Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 12,378 $208,140 +$187,034 1,683.18% 4
2025 Q3 49,994,786 $789,088,187 +$2,780,401 1,579% 112
2025 Q2 51,165,684 $475,330,436 -$6,689,427 929% 105
2025 Q1 48,567,553 $633,357,530 +$9,523,566 1,303% 92
2024 Q4 46,709,070 $813,618,424 +$75,118,533 1,742% 84
2024 Q3 36,338,664 $925,610,709 +$847,327,352 2,547% 68